Average rating: | Rated 5 of 5. |
Level of importance: | Rated 5 of 5. |
Level of validity: | Rated 5 of 5. |
Level of completeness: | Rated 5 of 5. |
Level of comprehensibility: | Rated 5 of 5. |
Competing interests: | I am a co-inventor on WO/2021/239623 / US 11,480,583 and WO/2023/204698. I am a consortium member of REPO-TRIAL which conduts the REPO-STROKE and REPO-HFpFF clinical trials. |
In the Introduction, the chemical name of ODQ misses the square brackets. Correct representation is 1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one.
Under Competing Interests, update the final sentence: "H.H.H.W.S and A.P. are inventors of WO/2023/204698 titled "Diagnosis and/or treatment of heart failure with preserved ejection fraction."